JPMorgan Chase & Co. Boosts Eli Lilly and Company (NYSE:LLY) Price Target to $900.00

Eli Lilly and Company (NYSE:LLY) had its price target upped by JPMorgan Chase & Co. from $850.00 to $900.00 in a research report report published on Wednesday, Benzinga reports. They currently have an overweight rating on the stock.

Several other brokerages have also recently weighed in on LLY. Bank of America boosted their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a buy rating in a research report on Friday, March 1st. Citigroup upped their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a buy rating in a research report on Tuesday, April 2nd. Truist Financial lifted their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a buy rating in a research report on Wednesday. The Goldman Sachs Group upped their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a neutral rating in a research report on Thursday, April 11th. Finally, Wells Fargo & Company lifted their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an overweight rating in a report on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $757.95.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $734.97 on Wednesday. The stock has a market cap of $698.52 billion, a PE ratio of 108.24, a P/E/G ratio of 1.46 and a beta of 0.37. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The business’s 50-day simple moving average is $761.06 and its two-hundred day simple moving average is $671.38. Eli Lilly and Company has a 52 week low of $419.80 and a 52 week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.62 EPS. As a group, analysts forecast that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Financial Management Network Inc. boosted its holdings in Eli Lilly and Company by 13.4% in the third quarter. Financial Management Network Inc. now owns 828 shares of the company’s stock worth $440,000 after acquiring an additional 98 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 3.1% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 242,558 shares of the company’s stock worth $130,285,000 after acquiring an additional 7,194 shares during the last quarter. 1834 Investment Advisors Co. boosted its position in shares of Eli Lilly and Company by 3.3% during the 3rd quarter. 1834 Investment Advisors Co. now owns 4,704 shares of the company’s stock worth $2,526,000 after purchasing an additional 150 shares during the period. Simon Quick Advisors LLC increased its holdings in Eli Lilly and Company by 41.4% in the 3rd quarter. Simon Quick Advisors LLC now owns 2,649 shares of the company’s stock valued at $1,423,000 after purchasing an additional 775 shares during the last quarter. Finally, VeraBank N.A. raised its position in Eli Lilly and Company by 1.9% in the third quarter. VeraBank N.A. now owns 3,747 shares of the company’s stock valued at $2,013,000 after purchasing an additional 70 shares during the period. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.